Hyperammonemic Coma—Barking Up the Wrong Tree by Rimar, Doron et al.
CASE REPORTS/CLINICAL VIGNETTES
Hyperammonemic Coma—Barking Up the Wrong Tree
Doron Rimar, MD
1,2, Eti Kruzel-Davila, MD
1, Guy Dori, MD, PhD
1, Elzbieta Baron, MD
1,
and Haim Bitterman, MD
1
1The Ruth and Bruce Rappaport Faculty of Medicine, Department of Medicine, Carmel Medical Center, Technion-Israel Institute
of Technology, Haifa, Israel, 34362;
2Department of Medicine A, Carmel Medical Center, 7 Michal Street, Haifa 34362, Israel.
Hepatic encephalopathy and myxedema coma share
clinical features: coma, ascites, anemia, impaired liver
functions, and a “metabolic” electroencephalogram
(EEG). Hyperammonemia, a hallmark of hepatic en-
cephalopathy, has also been described in hypothy-
roidism. Differentiation between the 2 conditions,
recognition of their possible coexistence, and the conse-
quent therapeutic implications are of utmost impor-
tance. We describe a case of an 82-year-old woman with
ahistory ofmild chronicliverdiseasewhopresentedwith
hyperammonemic coma unresponsive to conventional
therapy. Further investigation disclosed severe hypothy-
roidism. Thyroid hormone replacement resulted in gain
of consciousness and normalization of hyperammone-
mia. In patients with an elevated ammonia level, altered
mental status, and liver disease, who do not have a clear
inciting event for liver disease decompensation, over-
whelming evidence of hepatic decompensation, or who
do not respond to appropriate therapy for hepatic
encephalopathy, hypothyroidism should be considered
and evaluated.
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INTRODUCTION
Myxedema coma is a rare syndrome that represents the
extreme expression of hypothyroidism. The typical patient
presenting with myxedema coma is a woman in her 70s and
the cardinal manifestation is deterioration of mental status.
Physical findings often include hypothermia without shivering,
bradycardia, hypoventilation, macroglossia, hoarseness, dry
skin, and delayed tendon reflexes; if hypothyroidism is long
standing, there will also be accumulation of fluid rich in
mucopolysaccharides in extracellular space manifesting as
peripheral nonpitting edema, ascites, pleural and pericardial
effusion. Routine laboratory evaluation may indicate anemia,
hyponatremia, hypercholesterolemia, increased serum lactate
dehydrogenase and creatine kinase. Typical electrocardiogram
findings are varying degrees of blocks, low voltage, prolonged
QT interval, and flattened or inverted Twaves. Finally, the EEG
may show a pattern typical to metabolic coma, including
triphasic waves.
1
Hepatic encephalopathy is a metabolic coma, the hallmark
of which is hyperammonemia. Although not all patients with
hepatic encephalopathy present with hyperammonemia, and
hyperammonemia is not pathognomonic for hepatic encepha-
lopathy, the common practice is to consider patients with a
liver disease, hyperammonemia, and coma as suffering from
hepatic encephalopathy.
We report a case of hyperammonemic coma unresponsive to
conventional therapy. Further investigation disclosed severe
hypothyroidism. Thyroid hormone replacement resulted in
gain of consciousness and normalization of hyperammonemia.
The differentiation between myxedema coma and hepatic
encephalopathy, conditions which share many similarities, is
of utmost importance and carries therapeutic implication.
Case Report
An 82-year-old woman was admitted to the hospital in a state
of coma. She had been alert and functioning until 1 week
before admission, when she gradually became lethargic and
unresponsive.
The patient had a history of hypothyroidism, vitiligo,
essential hypertension, depressive disorder, and mild impair-
ment of liver function, which had not been investigated in the
past. Her chronic medication included amlodipine, sertraline,
furosemide, ramipril, atenolol, and levothyroxine.
On physical examination she was in a state of coma with a
Glasgow Coma Score of 5. Her rectal temperature was 36.1°C,
heart rate was 56 beats per minute, blood pressure 118/70 mmHg,
and respiration rate 20 per minute.
Examination of the abdomen revealed no organomegaly or
ascites.No clubbing,spider angiomas, or palmar erythema were
noted. Neurologically, she was unresponsive, Achilles tendon
reflexes were absent bilaterally, and flapping tremor was not
elicited.Therestofthephysicalexaminationwasunremarkable.
Blood tests revealed macrocytosis of 110 μm
3 (78–102 μm
3),
severe vitamin B12 deficiency 74 pg/mL (200–800 pg/mL),
and no antiparietal cell antibodies. Creatine kinase was
markedly elevated, 1,020 U/L (40–150 U/L ), and mild
abnormalities in enzymatic, cholestatic, and biosynthetic liver
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549function tests were noted: aspartate aminotransferase (AST)
232 U/L (0–35 U/L ), alanine aminotransferase (ALT) 65 U/L (0–
35 U/L ), gamma glutamyl transferase (GGT) 69 U/L (1–94 U/L ),
alkaline phosphatase (ALP) 142 U/L (30–120 U/L ), bilirubin
total 0.9 mg/dL (0.3–1 mg/dL), international normalized ration
(INR) 1.44, albumin 2.4 g/dL (3.5–5.5 g/dL). Her serum
ammonia level was distinctly elevated, 194 μmol/L (6–
47 μmol/L). Urine toxicity screen was negative. Thyroid-stimu-
lating hormone (TSH) level was ordered. Lumber puncture
results were not indicative of infection. A computed tomography
scan of the brain was normal. An electroencephalogram showed
a “metabolic pattern” of generalized slowing and triphasic
waves. Doppler ultrasound revealed a liver of normal span,
with coarse nonhomogenous texture. Hepatic veins were nor-
mal in diameter and no hepatofugal flow in the portal vein was
detected. A liver scan demonstrated colloid shift to the spleen
andbone marrow, consistent withchronic liver disease. Further
evaluation of liver disease revealed negative serology for HIV,
Hepatitis B and C viruses, Coxiella burnetii phase 1 and 2,
antismooth muscle, anti-LKM, antisoluble liver antigen and
antimitochondrial antibodies. An elevated antinuclear factor
titer, 1:640 (negative at 1:40) and hypergammaglobolinemia,
IgG concentration of 3,200 mg/dL (614–1,295 mg/dL) were
suggestive of autoimmune hepatitis type 1. At this point a drop
in blood pressure was noted and was evaluated by a 1-mcg
ACTH test, which revealed adrenal insufficiency: cortisol 0
minute—150 nmol/Liter (171–536 nmol/L at 8:00 A.M.) and
cortisol 30 minutes—200 nmol/L (>550 nmol/L or an increase
of > 200 nmol/L). Treatment of hepatic encephalopathy and
adrenal insufficiency with lactulose, neomycin, and hydrocor-
tisone was initiated. Blood pressure normalized; however, only
a mild improvement in the state of consciousness was noticed;
liver function test results worsened and her ammonia level did
not change. Thyroid function test results, received 3 days after
admission, revealed severehypothyroidism (thyroid stimulating
hormone 49 μU/mL [0.5–4.7 μU/mL] and free T4 <2.57 pmol/L
[10.3–35 pmol/L]). Antithyroid peroxidase and antithyroglobu-
lin antibody were negative. Ultrasound examination displayed
an enlarged thyroid gland with multiple ill-defined nodules
characteristic of Hashimoto’s Thyroiditis. Treatment with intra-
venous levothyroxine 100 μg was commenced and resulted in a
rapid (within 24 hours) regain of consciousness and a drop in
serum ammonia level to 64 μg/dL. Soon thereafter the EEG
pattern normalized, CK and liver function test results returned
to baseline. After regaining full consciousness, the patient
reported that she had discontinued levothyroxine therapy
4 months before admission.
DISCUSSION
We present a patient with hypothyroidism, adrenal insufficien-
cy, suspected autoimmune hepatitis and atrophic gastritis—a
combination that is consistent with autoimmune polyglandu-
lar syndrome type 2. Discontinuation of levothyroxine therapy
resulted in hyperammonemic coma with severe hypothyroid-
ism that was unresponsive to lactulose and neomycin, but
which was resolved after thyroid hormone replacement.
In this patient hyperammonemic coma may represent an
atypical case of myxedema coma in the setting of liver disease.
An alternative explanation may be that hypothyroidism was a
precipitant for decompensation of liver disease and thus
hyperammonemic coma was the manifestation of hepatic
encephalopathy.
Myxedema coma and hepatic encephalopathy share many
clinical features: coma, ascites, pleural effusion, peripheral
edema, clubbing, anemia, hypercholesterolemia, hyponatre-
mia, hypoglycemia, elevated liver enzymes level including
lactate dehydrogenase and metabolic pattern on EEG.
AnEEGpatternoftriphasicwaves,elevatedliverenzymes,and
hyperammonemia are rareand unfamiliar features of myxedema
coma, which may divert the clinical judgment from the correct
diagnosis and be confused with hepatic encephalopathy.
An EEG pattern of triphasic waves was first described in
hepatic encephalopathy by Bickford and Butt in 1955 and
became synonymous with hepatic encephalopthy (HE).
2 Nev-
ertheless, triphasic waves are not pathognomonic for hepatic
encephalopathy and have been reported in other metabolic
encephalopathies, the most common of which are renal
failure and anoxic injury.
3 To the best of our knowledge, only
1 report in the literature describes triphasic waves during
hypothyroidism.
4
Elevated liver enzymes may reflect the effect of hypothyroid-
ism on the liver or be related to a concomitant liver disease.
The association of hypothyroidism and liver diseases including
autoimmune hepatitis, primary biliary cirrhosis, and chronic
hepatitis C is not uncommon (6–13%).
5–7
The liver is not considered a hormonally regulated organ.
Nevertheless, hypothyroidism has a vast effect on liver func-
tion and structure. Thyroid hormones regulate hepatic mi-
tochondrial catabolism. An increase in liver enzymes
concentration, AST more than ALT, is often found.
8 An animal
study in hypothyroid rats has, however, shown that, whereas
ALT function (production of pyruvate) increases, AST function
(production of oxaloacetate) decreases.
9 Microscopic changes
including central congestive fibrosis have been described in
myxedema ascites.
10 In our patient, elevated liver enzymes,
AST more than ALT, may have been a consequence of either
hypothyroidism or autoimmune hepatitis. A high titer of
antinuclear antibody (ANA) and hypergammaglobolinemia in
the setting of autoimmune polyglandular syndrome type 2 are
suggestive of autoimmune hepatitis, yet a definite diagnosis
was not reached, as the patient declined a liver biopsy.
A retrospective review of the medical history of the patient
confirmed that increased plasma levels of liver enzymes in the
presence of normal TSH had repeatedly been recorded several
years before admission. Hence, in the presence of euthyroid-
ism, it is reasonable that some other smoldering chronic liver
disease, most probably autoimmune hepatitis, was present
before the occurrence of hypothyroidism.
The most common cause of hyperammonemia in adults is
liver cirrhosis. Rare causes of hyperammonemia include drug
toxicity (e.g., valproic acid, salicylates, and 5 fluorouracil), and
urinary tract infection with a urease-producing organism,
such as Klebsiella pneumonia, Proteus mirabilis, Corynebacte-
rium species, or Staphylococcus species.
11–13 Hyperammone-
miainourpatientwasatfirstattributedbyustodecompensation
of a chronic liver disease. Common precipitants of hyperammo-
nemia in patients with liver cirrhosis are delineated in the table.
Evaluation of our patient identified constipation and exacerba-
tion of autoimmune hepatitis to be possible inciting events for
hyperammonemia. However, lack of response to lactulose,
neomycin and steroids did not support this assumption. Prompt
response to thyroid hormone replacement suggested that hyper-
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hypothyroidism or that hypothyroidism was the inciting event
for liver decompensation and hepatic encephalopathy in the
setting of a chronic liver disease.
To date, 4 cases of hyperammonemia and myxedema coma
have been described in the literature.
14–17 All reported cases,
including ours, describe patients with an undiagnosed or fully
compensated liver disease. All cases presented a clinical
picture of hyperammonemic coma, unresponsive to lactulose
and neomycin therapy, which improved only after thyroid
hormone replacement. Precipitants for hepatic encephalopa-
thy were not evident.
Hyperammonemia has also been described in 3 patients
with hypothyroid myopathy and no known previous liver
disease, in whom a concomitant increase in transaminases,
and hyperammonemia attributed to increased catabolism of
muscle, completely resolved after gaining euthyroidism.
Hyperammonemia in this setting did not result in any
neurological impairment.
18
Hyperammonemia in hypothyroidism may be explained by
pathophysiological studies of the urea cycle in this condition.
In a rat liver model, hypothyroidism was associated with an
increased urea synthesis, attributed to an increase in urea
cycle enzyme activity.
9,19 However, when studied in hypothy-
roid women, a decreased urea synthesis rate, in comparison
with values measured in euthyroidism, was found.
20 Inefficient
urea synthesis during hypothyroidism, as was demonstrated
in vivo, is expected to result in an increased ammonia level.
Moreover, an increased load of nitrogen products during
hypothyroidisim may aggravate the hyperammonemic state.
Several mechanisms can explain the suspected increased
nitrogen load: 1) Decreased protein synthesis and increased
protein catabolism (attributed to a decrease in growth hor-
mone and to hypothyroid myopathy)
21,22; 2) Decreased intes-
tinal motility that promotes bacterial production of ammonia
and augments its absorption; and 3) decreased glutamine
synthetase activity that may diminish utilization of glutamine
by the urea cycle in the liver.
9
Despite the available information on mechanisms by which
hypothyroidism may impair liver functions, the exact role of
hypothyroidism in hyperammonemic coma as a direct inciting
event or a precipitant for decompensation of liver disease has
not yet been resolved.
It is of utmost importance to bear in mind the possibility of
combined hypothyroidism and liver disease in hyperammone-
mic coma and to carefully search for clues to each of these
conditions in physical examination, laboratory results, and
imaging studies. A careful physical examination may reveal
findings typical of myxedema such as dry cool skin, coarse,
sparse hair, and macroglossia, or findings suggestive of cirrho-
sis: jaundice, spider angiomas, caput medusa, Dupuytren’s
contracture, palmar erythema, fetor hepaticus, gynecomastia,
hair loss, paper money skin, parotid enlargement, clubbing,
and terry’s nails (white nails), all of which were missing in our
patient. Peripheral edema is typically nonpitting in myxedema,
in contrast to the typical pitting edema in liver disease. Tendon
reflexes are delayed in myxedema coma as was noticed in our
patient, whereas hyperreflexia, asterixis, and flapping tremor
are characteristic of hepatic encephalopathy. Laboratory work-
up may reveal pancytopenia caused by hypersplenism, a
characteristic of cirrhosis or elevated CPK and macrocitic
anemia more typical to myxedema. Finally, imaging studies
may help demonstrate pericardial effusion or an enlarged
thyroid gland, characteristic of myxedema or a nonhomo-
genous liver with hepatofugal flow in hepatic veins, charac-
teristic of cirrhosis.
In conclusion: in patients with an elevated ammonia level,
altered mental status, and liver disease, who do not have a
clear inciting event for decompensation of liver disease,
overwhelming evidence of hepatic decompensation, or who do
not respond to appropriate therapy for hepatic encephalopa-
thy, hypothyroidism should be considered and evaluated.
COMMON PRECIPITANTS OF HEPATIC
ENCEPHALOPATHY
Increased nitrogen load:
Excess of dietary protein
Azotemia
Constipation











Superimposed acute liver disease
Progressive liver disease
Portal systemic shunt
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